Status:
COMPLETED
Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe. The aim of this trial is to compare insulin degludec and insulin aspart (IDegAsp) co-formulations with separately injected, simultaneous doses of insulin degludec (i...
Eligibility Criteria
Inclusion
- Glycosylated haemoglobin A1c (HbA1c) below or equal to 10.0 % based on central laboratory results
- Diagnosed with type 1 diabetes and treated with insulin for above or equal to 12 months
- Body Mass Index (BMI) between 18.0 and 27.0 kg/m\^2 (both inclusive)
Exclusion
- A subject with a history of significant multiple drug allergies or with a known or suspected allergy to the trial product or any medicine chemically related to the trialproduct, as judged by the Investigator
- A subject who is known to have hepatitis or who is carrier of the Hepatitis B surface antibodies, or has a positive result to the test for HIV antigen (HBsAg) or Hepatitis C antibodies
- A subject who has participated in any other trials involving investigational products within the 3 months preceding the start of dosing
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT01868568
Start Date
April 1 2008
End Date
August 1 2008
Last Update
October 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuss, Germany, 41460